Adiponectin receptor R1 is upregulated by valproic acid but not by topiramate in human hepatoma cell line, HepG2

Seizure

Volumn 17, Issue 8, 2008, Pages 723-726

  Rauchenzauner, Markus ^a   Laimer, Markus ^a   Luef, Gerhard ^a   Kaser, Susanne ^a   Engl, Julia ^a   Tatarczyk, Tobias ^a   Ciardi, Christian ^a   Tschoner, Alexander ^a   Lechleitner, Monika ^a   Patsch, Josef ^a   Ebenbichler, Christoph F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adiponectin receptor; Insulin resistance; VPA

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; LACTATE DEHYDROGENASE; TOPIRAMATE; VALPROIC ACID;

ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPERLEPTINEMIA; INSULIN RESISTANCE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; WEIGHT GAIN;

ANTICONVULSANTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RECEPTORS, ADIPONECTIN; RNA, MESSENGER; TIME FACTORS; UP-REGULATION; VALPROIC ACID;

EID: 55549095128     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2008.03.002     Document Type: Article

References (24)

1. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
2. Greco R., Latini G., Chiarelli F., Iannetti P., and Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65 (2005) 1808-1809
3. Luef G., Abraham I., Hoppichler F., Trinka E., Unterberger I., Bauer G., et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 51 (2002) 1274-1278
4. Rauchenzauner M., Haberlandt E., Scholl-Bürgi S., Ernst B., Hoppichler F., Karall D., et al. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 49 (2008) 353-357
5. Qiao L., Schaack J., and Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 147 (2006) 865-874
6. Guerrini R., and Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 7 (2006) 811-823
7. Reife R., Pledger G., and Wu S.C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41 Suppl. 1 (2000) S66-S71
8. Picard F., Deshaies Y., Lalonde J., Samson P., and Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 8 (2000) 656-663
9. Wilkes J.J., Nelson E., Osborne M., Demarest K.T., and Olefsky J.M. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 288 (2005) E617-E624
10. Campfield L.A., Smith F.J., and Burn P. The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm Metab Res 28 (1996) 619-632
11. Bobbert T., Rochlitz H., Wegewitz U., Akpulat S., Mai K., Weickert M.O., et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54 (2005) 2712-2719
12. Fasshauer M., Paschke R., and Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie 86 (2004) 779-784
13. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
14. Neumeier M., Weigert J., Schaffler A., Weiss T., Kirchner S., Laberer S., et al. Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors. Biochem Biophys Res Commun 334 (2005) 924-929
15. Lagace D.C., McLeod R.S., and Nachtigal M.W. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 145 (2004) 5493-5503
16. Wilkes J.J., Nguyen M.T., Bandyopadhyay G.K., Nelson E., and Olefsky J.M. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-Fa-fed male Wistar rats. Am J Physiol Endocrinol Metab (2005)
17. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 117-121
18. Demir E., and Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol 22 (2000) 361-364
19. Luef G.J., Lechleitner M., Bauer G., Trinka E., and Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 55 (2003) 53-58
20. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
21. Valle M., Gascon F., Martos R., Bermudo F., Ceballos P., and Suanes A. Relationship between high plasma leptin concentrations and metabolic syndrome in obese pre-pubertal children. Int J Obes Relat Metab Disord 27 (2003) 13-18
22. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13 (2007) 332-339
23. Inukai K., Nakashima Y., Watanabe M., Takata N., Sawa T., Kurihara S., et al. Regulation of adiponectin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab 288 (2005) E876-E882
24. Staiger H., Kaltenbach S., Staiger K., Stefan N., Fritsche A., Guirguis A., et al. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53 (2004) 2195-2201